Attorney Jason Hatfield Featured in Arkansas Times for Lawyer of the Year, Best Lawyers in Arkansas
Jason M. Hatfield is one of only three lawyers in Arkansas to receive the 'Lawyer of the Year' distinction for plaintiff's personal injury litigation. These three attorneys represent the top of their professional field in Arkansas when it comes to representing those injured by another's negligence. Mr. Hatfield was also recognized as one of Arkansas' top attorneys for workers' compensation claims, helping injured workers fight for the compensation they deserve.
These distinctions aren't the first for Jason M. Hatfield this year. Mr. Hatfield was also named to the Mid-South Super Lawyers list in 2024 for the 11th time. He also received his third nomination to the Super Lawyers Top 50 list in 2024.
Admitted to the State Bar of Arkansas in 1997, Jason M. Hatfield has worked to secure significant verdicts for clients and support his colleagues' professional efforts ever since. His work includes serving on the Board of Governors of the Arkansas Trial Lawyers Association and as President of the Washington County Bar Association, among other roles.
Attorneys are chosen for the Best Lawyers list solely by the ranking of their professional peers. Lawyers vote on the work of other attorneys in their practice areas, ensuring that those casting votes fully understand the role's demands and the skills required to attain excellence. Attorney Jason Hatfield, along with other lawyers who receive this distinction, was chosen for the Best Lawyers distinction based on his reliability and integrity in professional service.
The 'Best Lawyers in Arkansas' list is compiled each year from The Best Lawyers in America, a research-based list that collects information about outstanding attorney efforts across a range of practice areas. Best Lawyers has been published yearly since 1983, covering attorneys in 148 specialties and all 50 U.S. states.
The Best Lawyers in America and Best Lawyers: Ones to Watch rankings are published annually by BL Rankings, LLC.
At the Law Office of Jason M. Hatfield, P.A., we are seasoned veterans of the Arkansas legal system. We have families who are proud to live, work, and play in Northwest Arkansas – from Fayetteville to Bentonville.
Law Office of Jason M. Hatfield, P.A.
1025 E Don Tyson Pkwy
Springdale, AR 72764
(479) 888-4789
Press Contact : Jason Hatfield
Distributed by Law Firm Newswire
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
3 hours ago
- New York Post
140-pound, 12-foot python captured near South Carolina high school — and it took 3 guys to wrangle it: ‘Damn, he's strong as hell!'
No thankssssss! A monster python on the loose in South Carolina was caught steps from a local high school Monday night — and it took three brave souls to wrangle the beast back into captivity. The python was found down the road from Mid-Carolina High School in Prosperity, with local animal lover Warren Gallman and his family working together to track down the reptile and wrestle it into submission. Advertisement 5 It took three people to carry the python out of the grass where it was hiding and get it safely into a bin. Facebook/Warren Gallman 'As you can see from my battle wounds, I'm about 220 pounds and it pulled me to the grass,' Gallman told News19. 'It was strong. I got a few cuts on my arm.' Reports about the beast — at least 12 feet long and around 140 pounds — first started coming in to local police weeks ago, and when someone posted on social media that they'd seen it two miles from his house, Gallman set out with his son, nephew and a neighbor to 'got get it.' Advertisement After about 15 minutes, they located it near a railroad crossing, and with cameras rolling, they grabbed and grappled with the snake to corral it, ABC Columbia reported. 'Damn, he's strong as hell!' Gallman was heard saying in the clip. 'Are you pulling or is he doing it? Goddamn! Y'all pardon my language.' 5 The python spent weeks on the loose, with officials suspecting it was a pet that either escaped or was abandoned. Facebook/Warren Gallman 5 The group found the massive python just down the road from a local high school after a neighbor spotted it. Facebook/Warren Gallman Advertisement The crew finally got the python into a large bin and closed the top and took it home where it became a neighborhood sensation. Gallman's son has a pet ball python already and was prepared to help care for their newly captured serpent. Newberry County Sheriff Lee Foster thanked the group for their hard work. 'Warren you and your friends are brave people and great Americans,' Foster wrote on Facebook. 'It is believed this was someone's pet and it was released because this type of snake is not native here,' he added. Advertisement Riverbanks Zoo and Garden's curator of herpetology, Sean Foley, identified the snake as an albino reticulated python and said it was not unheard of for owners to cut them loose after finding themselves in over their heads. 5 Gallman estimates the snake is between 12 and 15 feet and weighs around 140 pounds. Facebook/Warren Gallman 5 Gallman's son already has a pet python and is ready to take care of it until a proper sanctuary can be found. Facebook/Warren Gallman 'A lot of people buy these snakes when they're two or three feet long, and you've got a cage that's four feet long and that's fine for a couple of years, but eventually that snake's gonna get 15 plus feet long,' Foley told ABC. 'You need to make sure you can accommodate what that snake needs for its entire life — and that's a difficult situation, he added. Reticulated pythons are the longest snakes in the world and can grow to nearly 30 feet, according to Zoo Atlanta. They are non-venomous and typically kill their prey by wrapping their bodies around small animals to asphyxiate them. They are capable of killing and swallowing animals as large as deer and boar — and Gallman said the snake he caught seemed big enough to swallow a pet dog, cat, or even a 'very small child.' Advertisement 'It could cause some harm,' he said. Gallman has reached out to some zoos to see if they can take the python. And though he has been unsuccessful so far, he intends to keep searching until he finds a sanctuary that can take it.
Yahoo
a day ago
- Yahoo
Who is ketamine queen Jasveen Sangha? What is ketamine and why do people take ketamine?
The ketamine queen is pleading guilty to selling the fatal drug that killed "Friends" star Matthew Perry. The 54-year old actor, famous for his role as Chandler Bing on "Friends" was found floating face down in the his pool on Oct. 28, 2023. His cause of death was the result of "acute effects of ketamine" and subsequent drowning, according to the autopsy report. Perry suffered a decades-long battled with mental illness and alcohol and drug addictions through his own admission. Here's what to know. What is ketamine? Ketamine is a dissociative anesthetic that also has hallucinogenic effects. It is used medically for induction and maintenance of anesthesia and it is also used as a treatment for depression and pain management. The drug can distort perceptions of sight and sound, making the user disconnected or detached from their pain or environment. It is often abused for theses same qualities, in that it can also induce a state of calm, immobility and amnesia while under the influence. Ketamine comes in a clear liquid that can be injected or mixed into drinks. It also comes in a white or off-white powder form that can be snorted or smoked. Common street names for ketamine are cat tranquilizer, cat valium, jet K, kit kat, purple, Special K, super acid, super K, and vitamin K. What is ketamine used for? Ketamine is a very strong anesthetic used to prevent pain during surgery or other medical procedures. According to sources, ketamine is also marketed for the management of any number of different psychiatric illnesses such as depression, anxiety, and chronic pain among others. Who is the 'Ketamine Queen' Jasveen Sangha? Jasveen Sangha, 42, of North Hollywood is reportedly known as the Ketamine Queen, and has been in custody since Aug. 2024. She came into public view due to her connection to Perry's death in 2023, albeit her illiegal activities were also linked to the overdose death of another man, Cody McLaury in 2019. Prosecutors accused Sangha of working with Perry's acquaintance, Erik Fleming, and selling 51 vials of ketamine to Perry's live-in assistant Kenneth Iwamasa, which injected Perry with the ketamine drug, according to news reports. Fleming and Iwamasa previously reached plea deals with the prosecutors and now, as of Aug. 18, so has Sangha. Sangha has entered a plea deal in which she is pleading guilty to five charges: one count of maintaining a drug-involved premises, three counts of distribution of ketamine and one count of distribution of ketamine resulting in death or serious bodily injury. She will face a statutory maximum sentence of 20 years in federal prison on the drug-involved premises count, up to 10 years in federal prison for each ketamine distribution count, and up to 15 years in federal prison for the count of distribution of ketamine resulting in death or serious bodily injury. Maria Francis is a Pennsylvania-based journalist who covers trending topics across the Mid-Atlantic region. This article originally appeared on Who is ketamine queen Jasveen Sangha? Why do people take ketamine? Solve the daily Crossword
Business Wire
a day ago
- Business Wire
CorriXR Therapeutics Secures $1M Investment from State of Delaware
NEWARK, Del.--(BUSINESS WIRE)-- CorriXR Therapeutics, Inc., a pioneering oncology-focused biotherapeutics company, has announced a significant milestone with a $1M investment from the State of Delaware. This funding will be instrumental in advancing CorriXR's lead program aimed at developing next-generation treatments for solid tumors, with particular focus on head and neck, and lung cancers. This investment not only underscores the potential of CorriXR's cutting-edge therapies but also highlights Delaware's commitment to supporting innovative early-stage companies. This is how Delaware wins the future, with CorriXR demonstrating the power of turning research into real solutions. Share "We're excited to have the State of Delaware participate in our Series A financing round as we advance toward our first-in-human clinical trial,' said Eric Kmiec, Ph.D., founder & CEO of CorriXR. 'This investment will be critical as we complete preclinical studies, scale-up manufacturing, and prepare our investigational new drug (IND) submission.' The State of Delaware's investment in CorriXR is the first $1M investment from the Delaware Accelerator & Seed Capital Program (DASCP), one of four programs awarded under the State Small Business Credit Initiative (SSBCI) federal program from the U.S. Treasury Department. The Division of Small Business is administering Delaware's $60.9 million SSBCI award aimed at providing access to capital for start-up and early-stage businesses. 'Our first $1 million investment is proof that Delaware's path to becoming the Mid-Atlantic hub for Innovation is well underway,' said Delaware Division of Small Business Director CJ Bell. 'Supporting companies like CorriXR to scale isn't just good business – it's the blueprint for turning that vision into reality.' 'This is how Delaware wins the future, with CorriXR demonstrating the power of turning research into real solutions," said Delaware Governor Matt Meyer. "By working closely with experts at the Gene Editing Institute, CorriXR is making promising CRISPR therapies a reality for patients faster than ever. This is exactly why the SSBCI program exists—because supporting innovation today means better treatments, stronger businesses, and a brighter future for Delaware." About CorriXR Therapeutics CorriXR is developing genetic medicines to transform the treatment of solid tumors. CorriXR's patented non-viral gene editing tool disables transcription factor NRF2, which controls 200+ genes responsible for creating a pro-oncogenic tumor microenvironment. Knockout of NRF2 disrupts cancer cell survival mechanisms and sensitizes them to standard of care, and is being developed as a monotherapy, neoadjuvant or in combination with chemotherapy, radiotherapy, or immunotherapy. CorriXR's platform has potential applications in over 30 types of squamous cell carcinomas by improving treatment efficiency at lower doses, increasing patient eligibility, and reducing dropouts due to side effects—ultimately leading to improved patient outcomes. Learn more at
